Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MedPro Believes Needlyzer Meets Revised Cal/OSHA Standard

This article was originally published in The Gray Sheet

Executive Summary

Needle destruction devices can qualify as "engineering controls" as specified in California's revised Bloodborne Pathogen Standard, according to the Standards Board of the California Occupational Safety and Health (Cal/OSHA).

You may also be interested in...



Existing Safety Dental Needles Not Safer Than Traditional Needles, Study Says

Currently available dental needles with safety features designed to prevent accidental needlesticks are not superior to traditional needles in terms of safety, according to a study published in the July edition of the Journal of the California Dental Association.

California Safe Needle Law Could Presage Efforts By More States, OSHA

The implementation of legislation in California designed to reduce the incidence of accidental needlesticks among health care workers may prompt additional states to enact laws mandating the use of needles and other sharps designed with protective safety features.

FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility

The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT012236

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel